PMID: 7538978May 16, 1995Paper

Bispecific monoclonal antibody anti-CD3 x anti-tenascin: an immunotherapeutic agent for human glioma

International Journal of Cancer. Journal International Du Cancer
L Davico BoninoP G Natali

Abstract

Besides surgery, the therapeutic possibilities for the treatment of human gliomas include adoptive cellular immunotherapy, radioimmunotherapy, immunotherapy mediated by chemoimmunoconjugates and, more recently, bispecific monoclonal antibodies (biMAbs). Anti-CD3 x anti-tenascin (TN) is the first reagent of a number of biMAbs under investigation for prospective use in vivo to maximize the cell-mediated cytolytic potential of glioma patients. This biMAb originated from the fusion of 2 parental hybridomas, made resistant by retrovirus-mediated infection to the different metabolic drugs, geneticin and methotrexate, respectively. The resulting hybrid hybridomas were selected on the basis of the double specificity for CD3 and TN, cloned several times and grown under continuous metabolic pressure. The different families of recombinant antibodies were then purified by high-pressure liquid chromatography on hydroxylapatite columns. Immunohistochemical studies on tumor specimens of different origin and histotype have shown that the selected biMAb presented a distribution pattern similar to that of the parental anti-TN MAb, maintaining the same staining homogeneity and intensity. Moreover, the mitogenic activity of anti-CD3 x anti-TN biMA...Continue Reading

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M T JenningsJ R Shapiro
Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·E D LaywellD A Steindler
Apr 1, 1991·International Journal of Cancer. Journal International Du Cancer·P G NataliL Zardi
Dec 15, 1991·Journal of Immunological Methods·P Matzinger
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·L B DeMonteF Malavasi
Mar 1, 1989·The Journal of Cell Biology·M A Bourdon, E Ruoslahti
Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·F MalavasiG Camussi
Jan 1, 1987·Annual Review of Cell Biology·G R Martin, R Timpl
Mar 1, 1994·Immunology Today·F MalavasiK Mehta
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MerloG C Spagnoli

❮ Previous
Next ❯

Citations

Feb 5, 2003·Advanced Drug Delivery Reviews·Ying Cao, Laura Lam
Oct 11, 2003·Biotechnology Advances·A FunaroF Malavasi
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Sep 1, 2008·Expert Opinion on Drug Discovery·Lawrence G Lum, Zaid Al-Kadhimi
Oct 9, 2007·Nuclear Medicine and Biology·C Andrew Boswell, Martin W Brechbiel
May 10, 2019·International Journal of Laboratory Hematology·Marie C Béné
Aug 24, 2017·Pharmacology & Therapeutics·Z Wu, N V Cheung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Adhesion Molecules in the Brain

Cell adhesion molecules found on cell surface help cells bind with other cells or the extracellular matrix to maintain structure and function. Here is the latest research on their role in the brain.

Cellular Immunometabolism

Immunometabolism involves not only the way metabolites are digested by the immune system, but the way in which they can alter the pathway of the immune system. These responses occur in day-to-day healthy cell functioning, but can result in diseases, such as autoimmune disorders. Discover the latest research on cellular immunometabolism here.